Shares of Dyne Therapeutics (DYN) are up $6.40, or 37%, to $23.52 in pre-market trading after Novartis (NVS) announced an agreement to acquire Avidity Biosciences (RNA).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Positioned for Growth with FORCE Platform and Key Upcoming Catalysts
- Dyne Therapeutics: Promising Advancements in Neuromuscular Treatments Drive Buy Rating
- Dyne Therapeutics downgraded to Perform at Oppenheimer following additional data
- Dyne Therapeutics downgraded to Perform from Outperform at Oppenheimer
- Dyne announces additional one-year data from ACHIEVE study